AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 232 min read$MRK

Merck, Moderna Personalized MRNA Caner Vaccine Cuts Melanoma Recurrence Risk In Phase 3 Study

Merck (MRK) and Moderna (MRNA) reported Phase 3 trial results showing their personalized mRNA cancer vaccine, intismeran, combined with KEYTRUDA, reduced melanoma recurrence risk by 42% vs. KEYTRUDA alone. The two-year recurrence-free survival rate was 82.2% for the combination vs. 70.0% for KEYTRUDA. The companies plan to discuss results with regulators and advance further studies. MRK stock closed at $147.24, down 1.76%.

Original reporting
rttnews.com
Published Oct 23, 2026, 5:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck, Moderna Personalized MRNA Caner Vaccine Cuts Melanoma Recurrence Risk In Phase 3 Study — source image
Source · rttnews.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The data represents a material clinical milestone that could drive near‑term stock moves and long‑term pipeline valuation.

02

Market read

First report of pivotal trial success; high relevance for biotech investors.

03

What to watch

Potential safety signals in larger populations and competition from other immunotherapies could limit impact.

Relevance 9/10Novelty 9/10Timing: today

Background

Merck and Moderna announced Phase 3 results for a personalized melanoma vaccine, showing significant reduction in recurrence and metastasis.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Phase 3 trial of personalized mRNA cancer vaccine shows 42% reduction in melanoma recurrence risk.

Expected impact

likely upside as investors price in the efficacy results

Evidence & confidence

Phase 3 data is material and new; market typically reacts favorably to successful oncology trials.

$MRNABullishHigh confidence
Context

Moderna co‑developed the vaccine; trial success boosts its mRNA oncology pipeline.

Expected impact

likely upside driven by renewed confidence in its cancer vaccine platform

Evidence & confidence

First disclosure of pivotal trial success; investors view it as a catalyst for future revenue.

Market effects

Sector

Boosts biotech and oncology sectors as investors reassess pipeline valuations.

Regional

U.S. biotech stocks may see broader gains; European peers could benefit indirectly.

Global

Sets a precedent for mRNA cancer vaccines worldwide, potentially influencing global R&D funding.

Counterpoint

What could challenge this read

Skeptics may question durability of response and regulatory hurdles, tempering upside.

Key entities

  • Company
    Merck

    Pharmaceutical giant developing the vaccine.

  • Company
    Moderna

    mRNA technology partner.

Read at source← All news

StoryModerna and Merck shares tumble after apparent leak of Phase 3 melanoma vaccine data

Also covered by

6 outlets

Related articles

OCT 23
$MRNAHigh

Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations

Moderna (MRNA) shares dropped 25% despite positive cancer vaccine data, which reduced melanoma recurrence or death risk by 42% in certain patients. The stock remains up 530% in 2026. Analysts attribute the selloff to high expectations. The vaccine, paired with Merck's Keytruda, showed 82% of patients alive without recurrence at two years. Full phase 3 results are pending.

finance.yahoo.com2 min
OCT 23
$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).

finance.yahoo.com2 min
OCT 23
$MRNAHighAI 8/10

Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says

Moderna (MRNA) shares fell 17.6% on Oct. 22 after Phase 3 trial results for its cancer vaccine were leaked. The drop occurred despite positive results for the vaccine, developed with Merck (MRK). Analysts attributed the decline to a 'sell the news' event, with Bernstein maintaining a $45 price target and Wells Fargo suggesting concerns may be overdone. Merck shares also dropped 1.76%.

finance.yahoo.com2 min
OCT 23
$MRNAHighAI 9/10

Moderna stock plunges 25% after melanoma vaccine data leak

Moderna (MRNA) stock fell 25.2% to $183.88 on 22 October 2026 after leaked Phase 3 trial data for its melanoma vaccine showed a 42% risk reduction, below investor expectations of 49%. The selloff erased $24bn in market value. Merck (MRK), Moderna's partner, dropped 1%. Analysts attributed the reaction to high expectations and a sell-the-news move.

financial-news.co.uk2 min